
Case study
02 Feb 2021
Hematologic Malignancies Case Study
Overview
Successful Study Start-up for complex Phase I Gene Modified Advanced Therapy Medicinal Product (ATMP) TCR-T (cell immunotherapy) study during the COVID-19 pandemic.
Study Specifics
Countries: Netherlands, 1 site
Services: Full service
Type: Dose Escalation, Open Label, gene-modified Advanced Therapy Medicinal Product (ATMP) / Genetically Modified Organisms (GMO) TCR-T in various malignant hematology diseases